

New efficient and totally stereoselective copper allylic benzoyloxylation of sterol derivatives

Jean Michel Brunel,* Ludovic Billottet and Yves Letourneux

Laboratoire Synthèse et Etude de Substances Naturelles à Activités Biologiques (SESNAB), IMRN INRA 1111, Faculté des Sciences et Techniques de St Jérôme, Université Paul Cézanne, Avenue Escadrille Normandie Niémen, 13397 Marseille cedex 20, France

Received 1 July 2005; accepted 1 August 2005

Abstract—A new efficient and totally stereoselective copper allylic benzoyloxylation of sterol derivatives has been developed. This methodology has been successfully applied to the synthesis of 7α -hydroxy DHEA and 7α -hydroxy cholesterol in a two-step synthesis with high chemical yields (77% and 61% overall yield, respectively). A mechanistic rationale justifying the total stereoselectivity encountered has been proposed.

© 2005 Elsevier Ltd. All rights reserved.

1. Introduction

Stereoselective functionalization of unactivated olefins is a very active and challenging research area with many potential synthetic applications.¹ In this area, metal-induced allylic oxidation of alkenes appears to be one of the best methods of synthesis and has been the subject of several investigations.² Apart from radical-initiated reactions,³ reactions based on selenium⁴ or palladium⁵ systems have attracted considerable interest. Among all these methods, Kharasch and Sosnovsky were the first to report in 1958, the allylic oxidation of olefins with *tert*-butyl perbenzoate and a catalytic amount of a copper(I) salt.⁶ Since then, numerous systems have been proposed in order to improve the enantioselectivity of the copper catalyzed acetoxylation of cyclic alkenes using a *tert*-butyl hydroperoxide (TBHP)/acetic acid mixture as an oxidant.⁷ Surprisingly, little research has been devoted to allylic sterol derivatives. 7α -Hydroxy derivatives of oxysterols are of considerable interest because of their possible involvement in the regulation of cholesterol metabolism.⁸ Moreover, sterols bearing a hydroxyl group in position 7 have been shown to be selectively cytotoxic toward tumor cells cultured in vitro and possess immunosuppressive properties.⁹


To date, no efficient and totally stereoselective methods have been reported for the synthesis of the corresponding pure 7α - or 7β -hydroxy derivatives. Among the most popular methods, the reduction of 7-ketosterol derivatives is achieved with L-selectride or sodium borohydride/cerium trichloride agents, respectively.¹⁰ Nevertheless, the total stereoselectivity of such a reaction is difficult to achieve and the presence of the two diastereomers is always seen. In this context, allylic oxidation of olefins could constitute an interesting alternative. Herein, we report a new totally stereoselective copper allylic benzoyloxylation of sterol derivatives. A mechanistic rationale justifying the total stereoselectivity encountered and the synthesis of various important sterol compounds will be also discussed.

2. Results and discussion

In 1961, Starka reported the stereoselective oxidation of cholesteryl acetate in acetic acid with *tert*-butyl perbenzoate in the presence of a catalytic amount of cuprous bromide giving after treatment, 7α -hydroxycholesterylacetate in 65% yield.¹¹ In our hands, it was impossible to reproduce such results with only the starting material being recovered at the end of the reaction. Despite these surprising results, we examined the influence of solvents and reaction temperature on chemical yield by using cholesterylacetate **1a** as a test substrate and copper bromide (2 equiv) as copper source (Table 1).

* Corresponding author. Tel.: +33 04 91 28 85 50; fax: +33 04 91 28 84 40; e-mail: bruneljm@yahoo.fr

3 generates copper(III) benzoate **4**, which rapidly rearranges to give the expected product **2a** with regeneration of copper(I) source (Scheme 1).



Scheme 1. Mechanism for the copper allylic benzoyloxylation of cholesteryl acetate **1a**.

The total 7α stereoselectivity encountered can be rationalized through the three different pathways underlined in Scheme 2.


Path I is reasonable from a chemical point of view, but we have never been able to observe traces of the formation of derivative **8**. Path II involving the formation of

5α -copper(III) derivative **6**, which rearranges to the expected 7α -benzoate product **2a**, via a seven-membered intermediate, constitutes the unique possible reaction pathway proposal. A transition state model is proposed to account for the stereoselection in the reaction (Scheme 3).


In this favorable transition state assembly, copper benzoate attains an orientation in such a way that the benzoate oxygen attacks the allylic carbon, which is electrophilic in nature due to the coordination of the incipient double bond with Cu species, in an α -position generating exclusively 7α -benzoate cholesteryl derivative **2a**. Moreover, this transition state allows us to justify that the formation of 7β -parent derivative is totally excluded and will never be encountered whatever the experimental conditions applied since only attack in an α -position occurs.

In order to clarify the scope of the present reaction, we examined the oxidation of a series of cholesterol derivatives by using the best experimental conditions previously encountered. The results are summarized in Table 3.


Whatever be the nature of sterol derivative under consideration, the reaction proceeds in moderate to excellent chemical yields varying from 31% to 95% but always with a total stereoselectivity. This methodology



Scheme 2. Possible mechanisms for the stereoselective copper allylic benzoyloxylation of cholesteryl acetate **1**.



Scheme 3. Possible transition state for the total stereoselective benzoyloxylation of cholesteryl acetate **1**.

Table 3. Stereoselective copper allylic benzoyloxylation of various sterol derivatives


Entry ^a	Sterol derivative	R, Product	Yield (%) ^b	Diastereomeric ratio (α/β) ^c
1	1a	Ac, 2a	76	100/0
2	1b	COPh, 2b	69	100/0
3	1c	<i>tert</i> -Bu(Me) ₂ Si, 2c	66	100/0
4	1d	H, 2d	31	100/0
5	9	Ac, 10	95	100/0
6 ^d	11	Ac, 12	76	100/0
7	13	Ac, 14	88	100/0

^a Reactions performed on 4.6 mmol scale in refluxing CH₂Cl₂ over 12 h under an argon atmosphere.

^b Isolated yield after column chromatography.

^c Diastereomeric ratio α/β determined by ¹H and ¹³C NMR spectroscopy.

^d Reaction performed over 48 h.

**Scheme 4.** Synthesis of 7 α -hydroxy DHEA **15** and 7 α -hydroxy cholesterol **16**.

has been successfully applied to the synthesis of two important oxygenated cholesterol derivatives, namely 7 α -hydroxy DHEA¹³ and 7 α -hydroxy cholesterol¹⁰ in a two-step synthesis with high chemical yields (77% and 61% overall yield, respectively) (Scheme 4).

3. Conclusion

In conclusion, a new efficient and totally stereoselective copper allylic benzoyloxylation of sterol derivatives has been developed. Additional studies dealing with the scope and limitations of such a reaction are under current investigation.

4. Experimental

4.1. Materials and methods

¹H NMR and ¹³C NMR spectra were recorded on a Bruker AC300 spectrometer in CDCl₃ as solvent. The

chemical shifts (ppm) were determined relative to Me₄Si (¹H and ¹³C). Toluene, tetrahydrofuran (THF) were distilled from sodium/benzophenone ketyl immediately prior to use. Ethyl acetate and petroleum ether (35–60 °C) were purchased from SDS and used without any previous purification. Column chromatography were performed on SDS silica gel (70–230 mesh).

4.2. General procedure for stereoselective copper allylic benzoyloxylation of cholesteryl acetate **1a**

To a 50 mL two-necked round flask under argon were placed 2 g (4.6 × 10⁻³ mol) of cholesteryl acetate **1a** dissolved in 25 mL of dry CH₂Cl₂. Copper bromide (1.3 g, 9.2 × 10⁻³ mol) was subsequently added and the solution heated to reflux for 15 min. *tert*-Butyl peroxybenzoate (3.4 mL, 18.4 × 10⁻³ mol) was added dropwise and the reaction heated overnight. After completion of the reaction, the mixture was filtered through a pad of Celite. The solvents were removed in vacuo and the resulting yellow oil subjected to chromatography on silica gel column (petroleum ether/ethyl acetate = 9/1) to give the

expected 7 α -benzoyloxycholesterylacetate **2a** in 76% yield. White solid; mp 74 °C; ¹H NMR (CDCl₃, 300 MHz) δ 8.01–7.42 (m, 5H), 5.73–5.21 (m, 2H), 4.68–4.57 (m, 1H), 2.38–0.66 (m, 44H); ¹³C NMR (CDCl₃, 75 MHz) δ 170.73, 166.49, 147.35, 133.10, 131.41, 129.96, 128.74, 121.18, 73.57, 69.30, 56.42, 49.99, 43.88, 42.73, 39.83, 38.22, 37.82, 37.40, 36.60, 36.19, 28.38, 28.01, 24.46, 24.32, 23.20, 22.91, 21.71, 21.20, 19.13, 18.61, 11.88. MS *m/z*: 549.3 [M+1] for C₃₆H₅₂O₄.

4.3. Synthesis of 7 α -benzoyloxycholesteryl-3 β benzoate **2b**

69% yield; white solid; mp 92 °C; ¹H NMR (CDCl₃, 300 MHz) δ 8.01–7.37 (m, 10H), 5.53 (m, 1H), 5.42 (m, 1H), 4.85 (m, 1H), 2.77–0.70 (m, 41H); ¹³C NMR (CDCl₃, 75 MHz) δ 165.57, 165.10, 141.47, 132.17, 131.30, 129.84, 129.12, 124.02, 73.35, 73.01, 56.45, 55.91, 47.21, 39.90, 39.83, 37.98, 37.71, 37.36, 36.64, 28.58, 28.25, 28.10, 25.62, 24.25, 22.70, 21.90, 19.08, 11.92. MS *m/z*: 611.8 [M+1] for C₄₁H₅₄O₄.

4.4. Synthesis of 7 α -benzoyloxycholesteryl-3 β -*tert*-butyldimethylsilyloxy **2c**

66% yield; white solid; mp 71 °C; ¹H NMR (CDCl₃, 300 MHz) δ 8.08–7.44 (m, 5H), 5.71–5.21 (m, 1H), 3.54–3.47 (m, 1H), 2.35 to –0.05 (m, 57H); ¹³C NMR (CDCl₃, 75 MHz) δ 166.98, 166.52, 149.21, 133.28, 131.60, 130.51, 130.02, 128.71, 119.81, 72.30, 69.81, 56.49, 50.11, 43.96, 42.75, 39.85, 37.84, 38.23, 36.67, 36.21, 32.20, 30.11, 28.38, 26.29, 26.09, 24.35, 23.23, 22.94, 21.10, 19.17, 18.53, 18.24, 11.87, –4.19, –4.35. MS *m/z*: 621.4 [M+1] for C₄₀H₆₄O₃Si.

4.5. Synthesis of 7 α -benzoyloxycholesteryl-3 β ol **2d**

31% yield; viscous oil; ¹H NMR (CDCl₃, 300 MHz) δ 8.02–7.26 (m, 5H), 6.13–4.86 (m, 4H), 2.53–0.81 (m, 41H); ¹³C NMR (CDCl₃, 75 MHz) δ 165.34, 142.92, 134.77, 131.06, 130.92, 129.91, 129.76, 124.76, 78.48, 75.80, 57.28, 54.69, 51.94, 51.36, 46.74, 44.67, 43.87, 40.81, 40.74, 39.01, 37.37, 37.33, 37.03, 29.42, 29.26, 29.20, 25.09, 24.07, 23.81, 21.93, 19.91, 17.54, 13.14, 13.05. MS *m/z*: 507.4 [M+1] for C₃₄H₅₀O₃.

4.6. Synthesis of 7 α -benzoyloxy DHEA-acetate **10**

95% yield; white solid; mp 100 °C; ¹H NMR (CDCl₃, 300 MHz) δ 8.01–7.42 (m, 5H), 5.65 (m, 1H), 5.42 (m, 1H), 4.57 (m, 1H), 2.20–0.86 (m, 26H); ¹³C NMR (CDCl₃, 75 MHz) δ 220.11, 170.40, 166.80, 141.42, 132.17, 129.87, 129.12, 124.02, 74.80, 72.39, 49.59, 48.70, 46.54, 37.95, 37.71, 36.55, 35.77, 31.50, 27.70, 21.75, 21.58, 21.27, 19.04, 14.03. MS *m/z*: 451.1 [M+1] for C₂₈H₄₄O₅.

4.7. Synthesis of 7 α -benzoyloxystigmasteryl-3 β acetate **12**

76% yield; viscous oil; ¹H NMR (CDCl₃, 300 MHz) δ 8.20–7.48 (m, 5H), 5.75–5.25 (m, 2H), 4.55–4.75 (m,

1H), 2.49–0.63 (m, 46H); ¹³C NMR (CDCl₃, 75 MHz) δ 170.80, 166.46, 147.34, 138.48, 133.11, 131.35, 129.98, 128.74, 121.18, 73.59, 69.27, 56.06, 51.59, 50.10, 43.89, 42.59, 40.94, 39.53, 38.22, 37.82, 36.91, 36.57, 32.23, 29.20, 27.87, 25.76, 24.52, 24.24, 21.72, 21.47, 21.19, 19.36, 18.61, 17.88, 17.68, 12.62, 12.08. MS *m/z*: 575.3 [M+1] for C₃₈H₅₄O₄.

4.8. Synthesis of 7 α -benzoyloxy-5-androstene-3 β ,17 β diacetate **14**

88% yield; viscous oil; ¹H NMR (CDCl₃, 300 MHz) δ 8.05–7.45 (m, 5H), 5.75–5.73 (m, 1H), 4.69–4.55 (m, 1H), 2.41–0.80 (m, 31H); ¹³C NMR (CDCl₃, 75 MHz) δ 172.00, 171.09, 166.78, 147.85, 133.68, 131.38, 130.27, 129.23, 121.30, 83.15, 73.80, 68.92, 44.96, 44.55, 43.11, 38.57, 38.22, 37.13, 37.05, 36.83, 28.20, 28.04, 24.08, 22.08, 21.92, 21.05, 19.01, 12.23. MS *m/z*: 495.6 [M+1] for C₃₆H₃₈O₆.

4.9. Synthesis of 7 α -hydroxy DHEA **15**

77% overall yield (two steps); white solid; ¹H NMR (CDCl₃, 300 MHz) δ 5.55 (m, 1H), 4.78 (m, 1H), 3.54 (m, 1H), 2.72–0.86 (m, 25H); ¹³C NMR (CDCl₃, 75 MHz) δ 220.11, 141.00, 127.39, 74.69, 71.96, 50.13, 49.62, 48.95, 42.39, 39.40, 38.58, 32.12, 31.45, 21.90, 21.57, 19.04, 14.15. MS *m/z*: 305.4 [M+1] for C₁₉H₂₈O₃.

4.10. Synthesis of 7 α -hydroxycholesteryl-3 β ol **16**

61% overall yield (two steps); white solid; ¹H NMR (CDCl₃, 300 MHz) δ 5.63–5.61 (m, 1H), 3.88–3.83 (m, 1H), 3.65–3.55 (m, 1H), 2.35–0.70 (m, 43H); ¹³C NMR (CDCl₃, 75 MHz) δ 146.65, 124.25, 71.71, 65.75, 56.25, 49.81, 42.65, 42.54, 39.92, 39.70, 37.91, 37.79, 37.50, 36.51, 36.16, 31.75, 28.67, 28.40, 24.69, 24.11, 23.20, 22.96, 21.10, 19.13, 18.64, 12.03. MS *m/z*: 403.3 [M+1] for C₂₇H₄₆O₂.

References

- (a) Fukazana, T.; Hashimoto, T. *Tetrahedron: Asymmetry* **1995**, *4*, 2323–2327; (b) Gupta, A. K.; Jaszlauskas, R. J. *Tetrahedron: Asymmetry* **1993**, *4*, 879–883; (c) Asami, M.; Ishizaki, T.; Inoue, S. *Tetrahedron: Asymmetry* **1994**, *5*, 793–797.
- (a) Walling, C.; Zavitsas, A. A. *J. Am. Chem. Soc.* **1963**, *85*, 2084–2090; (b) Kochi, J. K. *J. Am. Chem. Soc.* **1962**, *84*, 774–784; (c) Goering, H. L.; Mayer, U. *J. Am. Chem. Soc.* **1964**, *86*, 3753–3756; (d) Bulman Page, P. C.; McCarthy, T. J. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon Press: Oxford, 1991; Vol. 7, pp 83–117; (e) Muzart, J. *Bull. Soc. Chim. Fr.* **1986**, 65–77; (f) Kochi, J. K. *Science* **1967**, *155*, 415–424.
- Stephenson, L. M.; Grdina, M. R.; Orfanopoulos, M. *Acc. Chem. Res.* **1980**, *13*, 419–425.
- (a) Umbreit, M. A.; Sharpless, K. B. *J. Am. Chem. Soc.* **1977**, *99*, 5526–5528; (b) Stevenson, L. M.; Speth, D. R. *J. Org. Chem.* **1979**, *44*, 4683–4689; (c) Sharpless, K. B.; Lauer, R. F. *J. Am. Chem. Soc.* **1972**, *94*, 7154–7155; (d)

- Sharpless, K. B.; Lauer, R. F. *J. Org. Chem.* **1974**, *39*, 429–430; (e) Reich, H. J. *J. Org. Chem.* **1974**, *39*, 428–429; (f) Engman, L. *J. Org. Chem.* **1989**, *54*, 884–890; (g) Wirth, T.; Häuptli, S.; Leuenberger, M. *Tetrahedron: Asymmetry* **1998**, *9*, 547–550.
5. (a) Greenberg, H.; Bäckvall, J. E. In *Transition Metals for fine Chemicals and Organic Synthesis*; Bolm, C., Beller, M., Eds.; VCH: Weinheim, 1998; (b) Heumann, A.; Akermarck, B. *Angew. Chem.* **1984**, *96*, 443–444; (c) Principato, B.; Maffei, M.; Siv, C.; Buono, G.; Peiffer, G. *Tetrahedron* **1996**, *52*, 2087–2096.
6. (a) Kharasch, M. S.; Sosnovsky, G. *J. Am. Chem. Soc.* **1958**, *80*, 756; (b) Kharasch, M. S.; Sosnovsky, G.; Yang, N. C. *J. Am. Chem. Soc.* **1959**, *81*, 5819–5824; (c) Sosnovsky, G.; Rawlinson, D. J. In *Organic Peroxides*; Svern, D., Ed.; J. Wiley: New York, 1970; Vol. 1; (d) Rawlinson, D. J.; Sosnovsky, G. *Synthesis* **1972**, 1–28.
7. (a) Brunel, J. M.; Legrand, O.; Buono, G. *C. R. Acad. Sci., Ser. IIc* **1999**, 19–23; (b) Andrus, M. B.; Lashley, J. C. *Tetrahedron* **2002**, *58*, 845–866.
8. (a) Kandutsch, A. A.; Chen, H. W.; Heiniger, H. J. *Science* **1978**, *4355*, 498–501; (b) Chen, H. W. *Fed. Proc.* **1984**, *43*, 126–130.
9. (a) Hietter, H.; Bischoff, P.; Beck, J. P.; Ourisson, G.; Luu, B. *Cancer Biochem. Biophys.* **1986**, *9*, 75–83; (b) Rong, S.; Bergmann, C.; Luu, B.; Beck, J. P.; Ourisson, G. *C. R. Acad. Sci., Ser. III* **1985**, *300*, 89–94.
10. (a) Amann, A.; Ourisson, G.; Luu, B. *Synthesis* **1987**, 1002–1005; (b) Kumar, V.; Amann, A.; Ourisson, G.; Luu, B. *Synth. Commun.* **1987**, *17*, 1279–1286.
11. (a) Starka, L. *Pharmazie* **1962**, 126–127; (b) Starka, L. *Collect. Czech. Chem. Commun.* **1961**, *26*, 2452–2456.
12. (a) Beckwith, A. L. J.; Evans, G. W. *Proceedings* **1962**, 63–64; (b) Denney, D. Z.; Appelbaum, A.; Denney, D. B. *J. Am. Chem. Soc.* **1962**, *84*, 4969–4971; (c) Beckwith, A. L. J.; Zavistas, A. A. *J. Am. Chem. Soc.* **1986**, *108*, 8230–8234; (d) Kochi, J. K.; Bemis, A. *Tetrahedron* **1968**, *24*, 5099–5113.
13. Akwa, Y.; Morfin, R. F.; Robel, P.; Baulieu, E. E. *Biochem. J.* **1992**, *288*, 959–964.